TNFSF10 and amyloidosis: Given that Aβ plaques deposition is a feature typical of AD pathogenesis and progression (Zhang et al. 2023b), and in light of the changes in the immune environment observed both in the brain and the spleen, we investigated whether the anti-TNFSF10 mAb treatment could affect amyloidosis in 3xTg-AD mice.